



uniQure to Participate at Multiple Upcoming Conferences

August 30, 2018

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in September:

• **Wells Fargo Securities 2018 Healthcare Conference, September 5 – 6, 2018 at the Westin Copley Place in Boston, MA.**

- Matt Kapusta, chief executive officer at uniQure, will present a corporate update on Wednesday, September 5th at 3:35 p.m. ET. The live webcast can be accessed through the link displayed in the [Investor section of the uniQure website](#). The webcast replay will be available for at least 72 hours following the live event.
- In addition, company management will host meetings with institutional investors.

• **Citi's 13th Annual Biotech Conference, September 5 – 6, 2018 at the Four Seasons Hotel in Boston, MA.**

- Matt Kapusta will participate in a panel discussion entitled, “*Gene Therapy: Present & Future*”, moderated by Citi analysts, on Thursday, September 6th at 10:00 a.m. ET. The live webcast can be accessed through the link displayed in the [Investor section of the uniQure website](#). The webcast replay will be available for at least 72 hours following the live event.
- In addition, company management will host meetings with institutional investors.

• **Goldman Sachs 8th Annual Biotech Symposium, September 7, 2018 at Goldman Sachs London Offices, in London, United Kingdom.**

- Sander van Deventer, M.D., Ph.D., chief scientific officer at uniQure, will be available for one-on-one meetings with institutional investors on Friday, September 7th.

• **2018 Janney Healthcare Conference, September 17, 2018 at the Union League Club in New York City.**

- Sander van Deventer, M.D., Ph.D., chief scientific officer, will present a corporate update on Monday, September 17th at 10:45 a.m. ET.
- In addition, company management will host meetings with institutional investors.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with liver/metabolic, central nervous system and cardiovascular diseases. www.uniQure.com

uniQure Contacts

For Investors:

Maria E. Cantor

Direct: 339-970-7536

Mobile: 617-680-9452

m.cantor@uniQure.com

Eva M. Mulder

Direct: +31 20 240 6103

Mobile: +31 6 52 33 15 79

e.mulder@uniQure.com

For Media:

Tom Malone

Direct: 339-970-7558

Mobile: 339-223-8541

t.malone@uniQure.com